

SEARCH REQUEST FORM

Access DB# 90146

Scientific and Technical Information Center

Requester's full Name: Devesh Khare Examiner #: 77931 Date: 3/27/2003
 Art Unit: 1623 Phone Number 605-1199 Serial Number: PCT/US01/05320 / 09/889,287
 Mail Box: CM1-8B19 and Bldg/Room Location: CM1-8A13 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See Bib Data Sheet Point of Contact: Mona Smith
 Inventors (please provide full names): See Bib Data Sheet Technical Information Specialist: CM1 6A01
 Tel: 308-3278

Earliest priority Filing Date: See Bib Data Sheet

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please carry out a structure search of the ~~2,2,2,2-tetrahydro-1,4-benzodioxin~~ compounds having the formula set forth in Claims 43-48 enclosed herewith. A search of a method for synthesis of these compounds, Claims 1, 20 and 38 is also requested. A copy of the claims is provided.

The Bib Data Sheet which discloses the inventor names, title of the invention, and the earliest priority filing date is also provided.

Note: Please return the copy of the claims with the search.

Thank you.

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>M. J. J. J.</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>X</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>3/29/03</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>4/24/03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>75</u>	Fulltext _____	Sequence Systems _____
Clerical prep time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>60</u>	Other _____	Other (specify) _____

PTO-1590 (1-2000)

STIC-STN Search

Khare PCT/US01/05320

Page 1

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil hcaplu

FILE 'HCAPLUS' ENTERED AT 15:05:44 ON 25 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Apr 2003 VOL 138 ISS 18

FILE LAST UPDATED: 24 Apr 2003 (20030424/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que

L2 1 SEA FILE=REGISTRY "9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)-"/CN
L3 SEL L2 1- CHEM : 3 TERMS
L4 43 SEA FILE=HCAPLUS L3
L5 19 SEA FILE=HCAPLUS L4 AND (SYNTHES? OR PREP? OR MANUF?)

=> d ibib abs hitrn 15 1-9

L5 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:117837 HCAPLUS

DOCUMENT NUMBER: 138:122813

TITLE: Process for preparing purine
arabinofuranosyl nucleosides via stereoselective
glycosylation of nucleobase salts

INVENTOR(S): Bauta, William E.; Schulmeier, Brian E.; Cantrell,
William R., Jr.; Lovett, Dennis; Puente, Jose

PATENT ASSIGNEE(S): Ilex Oncology Inc., USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011877	A2	20030213	WO 2002-US24392	20020801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, K2, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

Searched by M. Smith

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG


PRIORITY APPLN. INFO.:

US 2001-309590P P 20010802

OTHER SOURCE(S):

MARPAT 138:122813

GI



I

AB The present invention provides for the **prepn.** .beta.-adenine nucleosides I, wherein R is halogen, NH₂; R₁-R₃ are independently H, hydroxy protecting group; by coupling an adenine deriv. contg. an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl deriv., in the presence of a base and solvent. The present invention also provides for the stereoselective **prepn.** of 2-deoxy-.beta.-D-adenine nucleosides wherein a blocked 2-deoxy-.beta.-D-arabinofuranosyl halide is coupled with the salt of an adenine deriv. The forgoing aspects of the present invention are utilized in the **prepn.** of a clofarabine I (R = Cl, R₁-R₃ = H) wherein the ratio of .beta. to .alpha.-anomer is at least 99:1.

IT 123318-82-1P

RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (conformation; process for prepg. purine arabinofuranosyl nucleosides via stereoselective glycosylation of nucleobase salts)

L5 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:657258 HCAPLUS

DOCUMENT NUMBER: 136:6249

TITLE: **Synthesis and biological activity of 4'-C-hydroxymethyl-2'-fluoro-D-arabinofuranosylpurine nucleosides**

AUTHOR(S): Shortnacy-Fowler, Anita T.; Tiwari, Kamal N.; Montgomery, John A.; Secrist, John A., III

CORPORATE SOURCE: Southern Research Institute, Birmingham, AL, 35255-5305, USA

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2001), 20(8), 1583-1598

Searched by M. Smith

PUBLISHER: CODEN: NNNAFY; ISSN: 1525-7770
DOCUMENT TYPE: Marcel Dekker, Inc.
LANGUAGE: Journal
English

AB A series of 4'-C-hydroxymethyl-2'-fluoro-D-arabinofuranosylpurine nucleosides was prep'd. and evaluated for cytotoxicity. The details of a convenient synthesis of the carbohydrate precursor 4-C-hydroxymethyl-3,5-di-O-benzoyl-2-fluoro-.alpha.-D-arabinofuranosyl bromide are presented. Proof of the structure and configuration at all chiral centers of the sugars and the nucleosides were obtained by proton NMR. All five target nucleosides were evaluated for cytotoxicity in human tumor cell lines. The 4'-C-hydroxymethyl clofarabine analog showed slight cytotoxicity in CCRF-CEM leukemia cells.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:617838 HCAPLUS

DOCUMENT NUMBER: 135:180927

TITLE: Improved methods for synthesizing
2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-
arabinofuranosyl)-9h-purin-6-amine

INVENTOR(S): Montgomery, John A.; Fowler, Anita T.; Secrist, John
A., III

PATENT ASSIGNEE(S): Southern Research Institute, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060383	A1	20010823	WO 2001-US5320	20010216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, B2, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1261350	A1	20021204	EP 2001-910961	20010216
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003023078	A1	20030130	US 2001-889287	20010716
PRIORITY APPLN. INFO.:			US 2000-183422P P	20000218
			WO 2001-US5320 W	20010216

OTHER SOURCE(S): CASREACT 135:180927

AB This invention relates to improved methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-9h-purin-6-amine, a chemotherapeutic agent that is useful in the treatment of various malignancies. Thus, 2,6-dichloropurine in MeCN is treated with NaH and reacted with 2-deoxy-2-fluoro-3,5-di-O-benzoyl-.alpha.-D-arabinofuranosyl bromide; this product was suspended in MeOH and treated with NaOMe to give 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-6-methoxy-9h-purine in 60% yield; this was reacted with ammonia to provide

Searched by M. Smith

2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-9H-purin-6-amine in 78% yield. The present method results in increased yields over previously reported methods.

IT 123318-82-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(improved methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-9H-purin-6-amine)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:64771 HCAPLUS

DOCUMENT NUMBER: 134:296041

TITLE: Oligonucleotides containing 9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-adenine and -guanine: synthesis, hybridization and antisense properties

AUTHOR(S): Tennila, Tuula; Azhayeva, Elena; Vepsalainen, Jouko; Laatikainen, Reino; Azhayev, Alex; Mikhailopulo, Igor A.

CORPORATE SOURCE: Departments of Pharmaceutical Chemistry, University of Kuopio, Kuopio, FIN-70211, Finland

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2000), 19(10-12), 1861-1884

CODEN: NNNAFY; ISSN: 1525-7770

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:296041

AB Synthesis of 9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-adenine (I) and -guanine (II) was accomplished via the condensation of 2,6-dichloropurine with 2-deoxy-2-fluoro-1,3,5-tri-O-benzoyl-.alpha.-D-arabinofuranose as a key chem. step. Condensation of silylated N6-benzoyladenine with 2 gave, after deblocking and chromatog. sepn., I (14%), it's .alpha.-anomer (14%) and N7-.alpha.-isomer (25%). The PSEUROT anal. of N9-.beta.-D-arabinosides I and II manifested slight preference for the S rotamer (64%) for the former, and an equal population of the N and S rotamers for the latter. The arabinosides I and II were used for the prepn. of the resp. phosphoramidite building blocks for automated oligonucleotide synthesis. Four 15-mer oligonucleotides (ONs) complementary to the initiation codon region of firefly luciferase mRNA were prepd.: unmodified 2'-deoxy-ON (AS1) and contg. (i) I instead of the only A (AS2), (ii) II vs. 3-G from the 5'-terminus (AS3), and (iii) both arabinosides at the same positions (AS4). All these ONs display practically the same (i) affinity to both complementary DNA and RNA, and (ii) ability to inhibit a luciferase gene expression in a cell-free transcription-translation system.

IT 123318-82-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oligonucleotides contg. deoxyfluorobarabinofuranosyladenine and guanine synthesis hybridization and antisense properties)

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:703903 HCAPLUS

DOCUMENT NUMBER: 132:231574

Searched by M. Smith

TITLE: Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity
AUTHOR(S): Spasokoukotskaja, T.; Sasvari-Szekely, M.; Keszler, G.; Albertioni, F.; Eriksson, S.; Staub, M.
CORPORATE SOURCE: Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University of Medicine, Budapest, H-1444, Hung.
SOURCE: European Journal of Cancer (1999), 35(13), 1862-1867
CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Deoxycytidine kinase (dCK), one of the rate-limiting enzymes in the intracellular metab. of many antileukemic drugs, has been shown to be stimulated after treatment of human tonsillar lymphocytes by 2-chloro-2'-deoxyadenosine (cladribine, CdA). The present work presents a comparative study of different normal and malignant cells in respect to the activation of dCK by CdA. G-phase lymphocytes showed a higher sensitivity for dCK stimulation than S-phase cells. Normal and leukemic peripheral blood mononuclear cells, as well as the promyelocytic cell line HL60, responded to CdA treatment by a 2-5-fold increase in activity of dCK. However, no significant stimulation was detected either in CCRF-CEM T-lymphoblastoid cells or in K562 myeloid cells. Thymidine kinase activity was not stimulated in any cases. Treatment of these cells with several other analogs beside CdA, such as 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-fluoro-1-.beta.-D-arabinosyladenine (Fludarabine) and 1-.beta.-D-arabinosylcytosine (cytarabine, araC) gave results similar to those of CdA treatment. Enhancement of dCK activity could also be achieved with the topoisomerase II inhibitor etoposide. In contrast, 2-chlororiboadenosine had no effect on the dCK at concns. of .1 to .10 .mu.M, while deoxycytidine and 5-azadeoxycytidine caused slight inhibition. These results indicate that treatment of cells with several inhibitors of DNA synthesis potentiates the dCK activity. The drugs widely differ in their stimulatory effect on dCK, and there are also 'responsive' and 'nonresponsive' cells with respect to dCK activation. Thus, enhancement of the dCK activity by specific drugs in 'responsive' cells might give a rationale for combination chemotherapy.

IT 123318-82-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nucleoside analogs and etoposide effect on deoxycytidine kinase activity in normal and malignant cells)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:191826 HCAPLUS

DOCUMENT NUMBER: 130:217817

TITLE: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration

AUTHOR(S): Takahashi, Takeshi; Kanazawa, Junji; Akinaga, Shiro; Tamaoki, Tatsuya; Okabe, Masami
CORPORATE SOURCE: Cancer Chemotherapy, Pharmaceutical Research Inst., Kyowa Hakko Kogyo Co., Ltd., Shizuoka, 411, Japan

SOURCE: Cancer Chemotherapy and Pharmacology (1999), 43(3),
233-240

CODEN: CCPHDZ; ISSN: 0344-5704

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 2-Chloro-9-(2-deoxy-
2-fluoro-.beta.-D-

arabinofuranosyl) adenine (Cl-F-araA) is a novel deoxyadenosine analog, which inhibits DNA synthesis by inhibiting DNA polymerase .alpha. and ribonucleotide reductase. Cl-F-araA shows potent antiproliferative activity against several leukemic cell lines including those of human origin and is also effective against murine solid tumors, in particular being curative against colon tumors. It was investigated whether Cl-F-araA is effective against human colon tumors, in particular by oral administration, since it has improved stability compared with other deoxyadenosine analogs. Antiproliferative activity in vitro was detd. from cell counts. S.c. inoculated xenograft models and a liver micrometastases model were used for assessment of antitumor activity in vivo. Cl-F-araA showed potent antiproliferative activity against 4 human colon tumor cell lines (HCT116, HT-29, DLD-1, WiDr), with a 50% growth-inhibitory concn. (IC50) of 0.26 .mu.M with a 72-h exposure. This activity was greater than those of fludarabine desphosphate and cladribine, other deoxyadenosine analogs, which showed IC50 values of 19 and 0.35 .mu.M, resp. Cl-F-araA showed potent antitumor activity against 4 human colon tumor xenograft models (HT-29, WiDr, Co-3, COLO-320DM) in a 5-day daily administration schedule, which was shown to be the most effective of 3 administration regimens tested (single, twice-weekly, 5-day daily). In particular, oral administration showed superior activity, with a regressive or cytostatic growth curve, compared with i.v. administration. In addn., Cl-F-araA was effective at only 1/16 of the max. dose tested in a 10-day daily administration schedule. Therapeutic efficiency seemed to increase in proportion to the frequency of administration. Cl-F-araA also decreased liver micrometastases created by intrasplenic injection of human colon tumor cells, leading to complete suppression at the max. dose tested. These results suggest that Cl-F-araA might be clin. effective against human colon cancers using a daily oral administration schedule.

IT 123318-82-1, 2-Chloro-9-(2
-deoxy-2-fluoro-.beta.-D
-arabinofuranosyl) adenine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of 2-chloro-9-(
2-deoxy-2-fluoro-.beta.

-D-arabinofuranosyl) adenine against

human colon tumor xenografts by oral administration)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:171085 HCAPLUS

DOCUMENT NUMBER: 130:346991

TITLE: Comparison of the mechanism of cytotoxicity of
2-chloro-9-(2-
deoxy-2-fluoro-.
beta.-D-arabinofuranosyl)
adenine, 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-

AUTHOR(S): ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-.beta.-D-ribofuranosyl)adenine in CEM cells
Parker, William B.; Shaddix, Sue C.; Rose, Lucy M.;
Shewach, Donna S.; Hertel, Larry W.; Secrist, John A.,
III; Montgomery, John A.; Bennett, L. Lee, Jr.
CORPORATE SOURCE: Southern Research Institute, Birmingham, AL, USA
SOURCE: Molecular Pharmacology (1999), 55(3), 515-520
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental
Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In an effort to understand biochem. features that are important to the selective antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenine [Cl-F(.uparw.)-dAdo], we evaluated the biochem. pharmacol. of three structurally similar compds. that have quite different antitumor activities. Cl-F(.uparw.)-dAdo was 50-fold more potent as an inhibitor of CEM cell growth than were either 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-ribofuranosyl)adenine [Cl-F(.downarw.)-dAdo] or 2-chloro-9-(2-deoxy-2,2-difluoro-.beta.-D-ribofuranosyl)adenine [Cl-diF(.uparw..downarw.)-dAdo]. The compds. were similar as substrates of deoxycytidine kinase. Similar amts. of their resp. triphosphates accumulated in CEM cells, and the rate of disappearance of these metabolites was also similar. Cl-F(.uparw.)-dAdo was 10- to 30-fold more potent in its ability to inhibit the incorporation of cytidine into deoxycytidine nucleotides than either Cl-F(.downarw.)-dAdo or Cl-diF(.uparw..downarw.)-dAdo, resp., which indicated that ribonucleotide reductase was differentially inhibited by these three compds. Thus, the differences in the cytotoxicity of these agents toward CEM cells were not related to quant. differences in the phosphorylation of these agents to active forms but can mostly be accounted for by differences in the inhibition of ribonucleotide reductase activity. Furthermore, the inhibition of RNA and protein synthesis by Cl-F(.downarw.)-dAdo and Cl-diF(.uparw..downarw.)-dAdo at concns. similar to those required for the inhibition of DNA synthesis can help explain the poor antitumor selectivity of these two agents because all cells require RNA and protein synthesis.

IT 123318-82-1, 2-Chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenine

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(mechanism of cytotoxicity of chlorodeoxyfluoroarabinofuranosyl adenine in CEM cells)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:132780 HCAPLUS

DOCUMENT NUMBER: 126:139875

TITLE: Nucleotide analogs, their preparation, and pharmaceutical compositions containing them for topical treatment of proliferative disease of the skin

INVENTOR(S): Hostetler, Karl Y.

PATENT ASSIGNEE(S): Hostetler, Karl Y., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

Searched by M. Smith

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640166	A1	19961219	WO 1996-US10084	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5654286	A	19970805	US 1995-485025	19950607
AU 9662737	A1	19961230	AU 1996-62737	19960606
EP 831855	A1	19980401	EP 1996-921531	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002515018	T2	20020521	JP 1997-502193	19960606
PRIORITY APPLN. INFO.: US 1995-485025 A 19950607				
US 1993-60258 A2 19930512				
WO 1996-US10084 W 19960606				

OTHER SOURCE(S): MARPAT 126:139875

AB Pharmaceutical compns. are disclosed which contain mono-, di-, and triphosphate esters of antiproliferative nucleoside analogs, DNA chain-terminating dideoxynucleoside analogs and other nucleoside analogs for the topical treatment of hyperproliferative diseases of the skin (psoriasis, atopic dermatitis, basal cell carcinoma, etc.). The useful phosphate esters of the nucleoside analogs include phosphoramidates and phosphothiorates, as well as polyphosphates having C and S bridging atoms.

IT 123318-82-1DP, derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (nucleotide analogs, prepn., and pharmaceutical compns. for topical treatment of proliferative skin diseases)

L5 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:555956 HCAPLUS

DOCUMENT NUMBER: 125:237782

TITLE: Metabolism and actions of 2-chloro-2'-fluoroarabinosyladenine (chlorofluoroarabinosyladenine, ribonucleotide reductase, DNA synthesis, apoptosis)

AUTHOR(S): Xie, Kevin Chunxi

CORPORATE SOURCE: Health Science Center, Univ. of Texas, Houston, TX, USA

SOURCE: (1996) 227 pp. Avail.: From degree-granting institution
 From: Diss. Abstr. Int., B 1996, 57(4), 2507

DOCUMENT TYPE: Dissertation

LANGUAGE: English

AB Unavailable

IT 123318-82-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (metab. and action of chlorofluoroarabinosyladenine)

=> d ibib abs hitrn 15 10-19

L5 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:394751 HCAPLUS

DOCUMENT NUMBER: 125:104437

TITLE: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenine

AUTHOR(S): Xie, Kevin Chunxi; Plunkett, William

CORPORATE SOURCE: Dep. Clin. Invest., Univ. Texas M. D. Anderson Cancer Cent., Houston, TX, 77030, USA

SOURCE: Cancer Research (1996), 56(13), 3030-3037
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The action of the new adenine nucleoside analog 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenosine (Cl-F-ara-A) on DNA synthesis was evaluated both in whole cells and in vitro assay systems with purified DNA polymerases. [3H]Thymidine incorporation into DNA in human lymphoblastoid CEM cells was inhibited by Cl-F-ara-A in a concn.-dependent manner that was not reversed 72 h after removal of Cl-F-ara-A from the medium. Deoxynucleotide pools were depressed after incubation of Cl-F-ara-A for 3 h and only partially recovered following washing the cells into drug-free medium. The most pronounced decrease occurred in the dCTP pool, quant. followed by the dATP, dCTP, and dTTP pools. This was in concordance with the results of in situ assays of ribonucleotide reductase, which demonstrated profound inhibition of CDP redn. in cells incubated with Cl-F-ara-A; redn. of ADP, GDP, and UDP were affected to lesser extents. Reductase activity was inversely correlated with the cellular Cl-F-ara-ATP level, and inhibition of the enzyme was satd. when cellular Cl-F-ara-ATP reached 25 .mu.M. In vitro DAN primer extension assays indicated that Cl-F-ara-ATP competed with dATP for incorporation into A sites of the extending DNA strand catalyzed by both human DNA polymerases .alpha. and .epsilon.. The incorporation of Cl-F-ara-AMP into DNA inhibited DNA strand elongation; the most pronounced effect was obsd. at Cl-F-ara-ATP:dATP values >1. The sustained inhibition of ribonucleotide reductase and the consequent depletion of deoxynucleotide triphosphate pools results in a cellular concn. ratio of dATP to Cl-F-ara-ATP, which favors analog incorporation into DNA, an action that has been strongly correlated with loss of viability. The results are discussed in relation to the antitumor mechanism of action of Cl-F-ara-A.

IT 123318-82-1, 2-Chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenine

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with chloro(deoxyfluoroarabinofuranosyl)adenine in relation to antitumor activity)

L5 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:448973 HCAPLUS
 DOCUMENT NUMBER: 122:260176
 TITLE: Preparative high-performance liquid chromatographic separation of fluorodeoxy sugars
 AUTHOR(S): Evangelisto, Mary F.; Adams, Richard E.; Murray, William V.; Caldwell, Gary W.
 CORPORATE SOURCE: The R.W. Johnson Pharmaceutical Research Institute, 1000 Route 202, Raritan, NJ, 08869-0602, USA
 SOURCE: Journal of Chromatography, A (1995), 695(1), 128-31
 CODEN: JCRAEY; ISSN: 0021-9673
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Normal- and reversed-phase preparative chromatog. methods were developed to isolate gram quantities of anal. pure 6-amino-2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-9H-purine (arafluoro-2-CdA; RWJ 29727) and its .alpha.-anomer (RWJ 48667). The complex reaction mixt. (.apprx.171 g), from a Parr Bomb synthesis, was prepurified by normal-phase chromatog. to yield .apprx.40 g. Twelve reversed-phase preparative isolations were run on a custom-packed YMC column to yield .apprx.12 g of arafluoro-2-CdA (99.7%) and .apprx.3 g of the .alpha.-anomer (99.2%).

IT 123318-82-1P

RL: PUR (Purification or recovery); PREP (Preparation)
 (preparative HPLC sepn. of fluorodeoxy sugars)

L5 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:383007 HCAPLUS
 DOCUMENT NUMBER: 122:291456
 TITLE: Antineoplastic 2'-fluoro-2-haloarabinoadenosines and their pharmaceutical compositions
 INVENTOR(S): Montgomery, John A.; Secrist, John A., III
 PATENT ASSIGNEE(S): Southern Research Institute, USA
 SOURCE: U.S., 8 pp. Cont.-in-part of U.S. 5,034,518.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5384310	A	19950124	US 1991-693646	19910510
US 5034518	A	19910723	US 1989-355358	19890523
AT 147751	E	19970215	AT 1990-909080	19900523
ES 2098266	T3	19970501	ES 1990-909080	19900523
CA 2102782	AA	19921111	CA 1992-2102782	19920507
WO 9220347	A1	19921126	WO 1992-US3889	19920507
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
EP 595826	A1	19940511	EP 1992-912163	19920507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507644	T2	19940901	JP 1992-500121	19920507
US 5661136	A	19970826	US 1994-320879	19940921
PRIORITY APPLN. INFO.:			US 1989-355358	A2 19890523
			US 1991-693646	A 19910510
			WO 1992-US3889	W 19920507

Searched by M. Smith

OTHER SOURCE(S):
GI

MARPAT 122:291456



AB The present invention is directed to certain 2'-fluoro; 2-substituted purine nucleosides I (wherein R, each which may be the same or different, is hydrogen or a protecting group; wherein Z is a halogen of the group F, Cl, and Br; and pharmaceutically acceptable salts thereof, said compn. being in combination with a pharmaceutically acceptable carrier for oral, topical, or parenteral administration) which are toxic to cancerous cell lines. Cytotoxicity [as IC₅₀(.mu.M)] of 2-haloadenine nucleosides against cancer cells (3 human cell lines and a murine leukemia line): from 0.003 to 4. Studies with the P388 leukemia cell line in mice indicate that the most effective compd. of the present invention is 2-chloro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-9H-purin-6-amine: at a dose of 20 mg/kg, median % ILS (increase in life span) was 220%.

IT 123318-82-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antineoplastic 2'-fluoro-2-haloarabinoadenosines)

L5 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:442767 HCAPLUS

DOCUMENT NUMBER: 121:42767

TITLE: Pharmaceutical compositions containing
2-halo-2'-deoxyadenosines in the treatment of
rheumatoid arthritis

INVENTOR(S): Carson, Dennis A.; Carrera, Carlos J.

PATENT ASSIGNEE(S): Scripps Research Institute, USA

SOURCE: U.S., 25 pp. Cont.-in-part of U.S. 5,106,837.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5310732	A	19940510	US 1992-838546	19920219
US 5106837	A	19920421	US 1990-460351	19900103

Searched by M. Smith

WO 9316706 A1 19930902 WO 1993-US1467 19930218
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR,
LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG
AU 9337249 A1 19930913 AU 1993-37249 19930218
AU 682818 B2 19971023
CH 684310 A 19940831 CH 1993-3143 19930218
EP 626853 A1 19941207 EP 1993-906071 19930218
EP 626853 B1 20000426
R: AT, BE, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
HU 68030 A2 19950529 HU 1994-2392 19930218
HU 218656 B 20001028
JP 07507540 T2 19950824 JP 1993-514960 19930218
BR 9305907 A 19971021 BR 1993-5907 19930218
RU 2130308 C1 19990520 RU 1994-38043 19930218
AT 192045 E 20000515 AT 1993-906071 19930218
US 5541164 A 19960730 US 1994-233056 19940426
US 5506213 A 19960409 US 1994-246328 19940519
CA 2191230 AA 19951207 CA 1994-2191230 19940526
CA 2191230 C 20010227
WO 9532718 A1 19951207 WO 1994-US5971 19940526
W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9474707 A1 19951221 AU 1994-74707 19940526
JP 10505323 T2 19980526 JP 1994-500782 19940526
NO 9402765 A 19940913 NO 1994-2765 19940725
US 5506214 A 19960409 US 1994-256931 19940727
FI 9403805 A 19941019 FI 1994-3805 19940818
AU 9918593 A1 19990506 AU 1999-18593 19990304
AU 735319 B2 20010705
PRIORITY APPLN. INFO.:
US 1986-825215 B2 19860203
US 1988-169618 B2 19880316
US 1989-323350 B2 19890314
US 1990-460351 A2 19900103
US 1992-838546 A1 19920219
WO 1993-US1467 A 19930218
US 1994-233056 A3 19940426
AU 1994-74707 A3 19940526
WO 1994-US5971 A 19940526
AB The title compns. contg. novel adenine derivs. are prepd. to
treat monocyte-mediated disorders such as rheumatoid arthritis and
multiple sclerosis. Exposure of cultured human monocytes to 20 nm
2-chlorodeoxyadenosine over a 5 days culture period at 37.degree. killed
50% of monocytes. Thus, 2,6-dichloro-9,1'(3'-O-acetyl-5'-O-benzoyl-2'-
deoxy-2'-fluoro-beta-D-arabinofuranosyl)-9-purine (prepn. given)
was reacted with methanolic ammonia to produce 2-chloro-9-beta-2'-deoxy-21-
fluoro-D-arabinofuranosyladenine (I). A tablet contained I 1, starch 40,
modified starch 10, Mg stearate 1-5 mg, and CaHPO4 q.s.
IT 123318-82-1P
RL: PREP (Preparation)
(prepn. of, pharmaceutical compns. contg., for treatment of
rheumatoid arthritis)
L5 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:192189 HCAPLUS
DOCUMENT NUMBER: 118:192189
TITLE: 2'-fluoro-2-substituted adeninyalarabinosides as
anticancer agents

INVENTOR(S): Montgomery, John A.; Secrist, John A.
 PATENT ASSIGNEE(S): Southern Research Institute, USA
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9220347	A1	19921126	WO 1992-US3889	19920507
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5384310	A	19950124	US 1991-693646	19910510
EP 595826	A1	19940511	EP 1992-912163	19920507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507644	T2	19940901	JP 1992-500121	19920507
PRIORITY APPLN. INFO.:			US 1991-693646	A 19910510
			US 1989-355358	A2 19890523
			WO 1992-US3889	W 19920507
OTHER SOURCE(S):		MARPAT 118:192189		
GI				



AB Title compds. I (R = H, protective group; R1 = F, Cl, Br) were **prepd.** Thus, I (R = H, R1 = Cl) was obtained in 42.3% yield by treating the protected 2,6-dichloropurine analog with NH3 in EtOH. I (R = H, R1 = Cl) had a cytotoxic ED50 against H.Ep-2 cells of 0.012 .mu.M, cf. 0.03 for the 2'-deoxy analog.

IT 123318-82-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and cytotoxicity of)

L5 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:152261 HCAPLUS


DOCUMENT NUMBER: 116:152261

TITLE: Synthesis and biological activity of
 2'-fluoro-2-halo derivatives of 9-.beta.-D-
 arabinofuranosyladenine


AUTHOR(S): Montgomery, John A.; Shortnacy-Fowler, Anita T.;
 Clayton, Sarah D.; Riordan, James M.; Secrist, John
 A., III

Searched by M. Smith


CORPORATE SOURCE: South. Res. Inst., Birmingham, AL, 35255-5305, USA
 SOURCE: Journal of Medicinal Chemistry (1992), 35(2), 397-401
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I



II



III



IV

AB The synthesis of 2-halo-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)adenines I (R = Br, Cl) by coupling the 2,6-dihalopurine with 2-deoxy-2-fluoro-D-arabinofuranosyl bromide II followed by replacement of the 6-halogen with concomitant removal of the acyl blocking groups is described. 2-Fluoroadenine deriv. I (R = F) had to be prepd. by the diazotization-fluorination of 2-aminoadenine nucleoside III (R1 = NH2, R2 = Ac). All three nucleosides provided good increases in life span of mice inoculated with P388 leukemia. The best results were obtained when the compds. were administered q3h.times.8 on days 1, 5, and 9 after implantation of the leukemia cells. The 2',3'-dideoxynucleoside IV (R3 = H), prepd. by deacetylation of III (R1 = F, R2 = Ac) and deoxygenation of the resultant III (R1 = F, R2 = H) followed by removal of the benzoyl group of IV (R3 = Bz), was slightly active against HIV in cell culture.

IT 123318-82-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and antitumor activity of)

L5 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1991:421747 HCAPLUS
 DOCUMENT NUMBER: 115:21747

Searched by M. Smith

TITLE: Effects of 2-chloro-9-(
2-deoxy-2-fluoro
-.beta.-D-arabinofuranosyl
)adenine on K562 cellular metabolism and the
inhibition of human ribonucleotide reductase and DNA
polymerases by its 5'-triphosphate

AUTHOR(S): Parker, William B.; Shaddix, Sue C.; Chang, Chi
Hsiung; White, E. Lucile; Rose, Lucy M.; Brockman, R.
Wallace; Shortnacy, Anita T.; Montgomery, John A.;
Secrist, John A., III; Bennett, L. Lee, Jr.

CORPORATE SOURCE: Kettering-Meyer Lab., South. Res. Inst., Birmingham,
AL, 35205, USA

SOURCE: Cancer Research (1991), 51(9), 2386-94
CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 2-Chloro-9-(2-deoxy-
2-fluoro-.beta.-D-
arabinofuranosyl)-adenine (Cl-F-ara-A) has activity
against the P388 tumor in mice on several different schedules. Biochem.
studies with a chronic myelogenous leukemia cell line (K562) grown in cell
culture have been done in order to better understand its mechanism of
action. Cl-F-ara-A was a potent inhibitor of K562 cell growth. Only 5 nM
inhibited K562 cell growth by 50% after 72 h of continuous incubation.
The 5'-triphosphate of Cl-F-ara-A was detected by strong anion exchange
chromatog. of the acid-sol. ext. of K562 cells incubated with Cl-F-ara-A.
Competition studies with natural nucleosides suggested that deoxycytidine
kinase was the enzyme responsible for the metab. to the monophosphate.
Incubation of K562 cells for 4 h with 50 nM Cl-F-ara-A inhibited the
incorporation of [3H]thymidine into the DNA by 50%. Incubation with 0.1,
1, or 10 .mu.M Cl-F-ara-A for 4 h depressed dATP, dCTP, and dGTP pools but
did not affect TTP pools. Similar inhibition of deoxyribonucleoside
triphosphate pools was seen after incubation with 2-chloro-2'-
deoxyadenosine. Both Cl-F-ara-ATP and Cl-dATP potently inhibited the
redn. of ADP to dADP in crude exts. of K562 cells (concn. producing 50%
inhibition, 65 nM). The effect of Cl-F-ara-ATP on human DNA polymerases
.alpha., .beta., and .gamma. isolated from K562 cells grown in culture was
detd. and compared with those of Cl-dATP and 9-.beta.-D-arabinofuranosyl-2-
fluoroadenine triphosphate (F-ara-ATP). Cl-F-ara-ATP was a potent
inhibitor of DNA polymerase .alpha.. Inhibition of DNA polymerase .alpha.
was competitive with respect to dATP (Ki of 1 .mu.M). The three analog
triphosphates were incorporated into the DNA by DNA polymerase .alpha. as
efficiently as dATP. The incorporation of Cl-F-ara-AMP inhibited the
further elongation of the DNA chain, similarly to that seen after the
incorporation of F-ara-AMP. Extension of the DNA chain after the
incorporation of Cl-dAMP was not inhibited as much as it was with either
Cl-F-ara-AMP or F-ara-AMP. Cl-F-ara-ATP was not a potent inhibitor of DNA
polymerase .beta., DNA polymerase .gamma., or DNA primase. These results
indicate that the inhibition of DNA synthesis by Cl-F-ara-A was
due to the inhibition of ribonucleotide reductase activity and inhibition
of chain elongation by DNA polymerase .alpha. and that, with respect to
inhibition of these enzymes, Cl-F-ara-A incorporates the best properties
of F-ara-A and 2-chloro-2'-deoxyadenosine into one compd.

IT 123318-82-1

RL: PRP (Properties)


(antitumor effect of, inhibition of human ribonucleotide reductase and
DNA polymerase by its triphosphate in)

L5 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2003 ACS

Searched by M. Smith

ACCESSION NUMBER: 1991:409260 HCAPLUS
 DOCUMENT NUMBER: 115:9260
 TITLE: Preparation of 2-halo-9-(2-deoxy-2-fluoro-
 .beta.-D-arabinofuranosyl)adenine nucleosides as
 anticancer agents
 INVENTOR(S): Montgomery, John A.; Secrist, John A., III
 PATENT ASSIGNEE(S): Southern Research Institute, USA
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9014352	A1	19901129	WO 1990-US2927	19900523
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 5034518	A	19910723	US 1989-355358	19890523
AO 9058315	A1	19901218	AU 1990-58315	19900523
EP 473708	A1	19920311	EP 1990-909080	19900523
EP 473708	B1	19970115		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05502014	T2	19930415	JP 1990-508789	19900523
JP 3160288	B2	20010425		
AT 147751	E	19970215	AT 1990-909080	19900523
ES 2098266	T3	19970501	ES 1990-909080	19900523
PRIORITY APPLN. INFO.:			US 1989-355358	A 19890523
			WO 1990-US2927	A 19900523
OTHER SOURCE(S):		MARPAT 115:9260		
GI				



AB The title compds. (I; Z = F, Cl, Br; R = H, acyl), useful in treatment of cancer, e.g., chronic lymphocytic leukemia, were prepd. Glycosylation of 2,6-dibromopurine with .beta.-D-arabinofuranosyl bromide II gave arabinofuranosyldibromopurine deriv. which was treated by ethanolic NH₃ to give, after hydrolysis (LiOH), I (Z = Br, R = H), which had an IC₅₀ of 0.60 .mu.M against L1210 cells.
 IT 123318-82-1P

Searched by M. Smith

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as anticancer agent)

L5 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:491460 HCAPLUS

DOCUMENT NUMBER: 113:91460

TITLE: Substituted adenine derivatives useful as therapeutic agents

INVENTOR(S): Carson, Dennis A.; Carrera, Carlos J.

PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8908658	A1	19890921	WO 1989-US1088	19890316
W: AD, DK, FI, JP, KR, NO				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8934105	A1	19891005	AU 1989-34105	19890316
AU 626296	B2	19920730		
EP 364559	A1	19900425	EP 1989-904431	19890316
EP 364559	B1	19950920		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03501258	T2	19910322	JP 1989-504299	19890316
JP 3090456	B2	20000918		
AT 128141	E	19951015	AT 1989-904431	19890316
CA 1339964	A1	19980721	CA 1989-593979	19890316
DK 8905721	A	19891115	DK 1989-5721	19891115
DK 170629	B1	19951120		
NO 8904558	A	19891115	NO 1989-4558	19891115
CA 2191230	AA	19951207	CA 1994-2191230	19940526
CA 2191230	C	20010227		
AU 9474707	A1	19951221	AU 1994-74707	19940526
JP 10505323	T2	19980526	JP 1994-500782	19940526
AU 9918593	A1	19990506	AU 1999-18593	19990304
AU 735319	B2	20010705		
PRIORITY APPLN. INFO.:			US 1988-169618	A 19880316
			US 1989-323350	A 19890314
			WO 1989-US1088	A 19890316
			AU 1994-74707	A3 19940526
			WO 1994-US5971	A 19940526

OTHER SOURCE(S): MARPAT 113:91460

GI



AB Substituted adenine derivs. I (e.g. Z = O or absent; Y = H or a substituent contg. 1-20 atoms that is free from net ionic charge at physiol. pH values; X = H or F; when Z is absent, X = F; Y is H only when Z is present and X = F) are effective in treating autoimmune diseases and monocyte-mediated disorders. For treating monocyte-mediated diseases, an antimicrobial agent in addn. to I may be administered. EDs of I for treating monocyte-mediated disease, autoimmune disease (i.e. rheumatoid arthritis), and AIDS are claimed. No therapeutic tests are given. In vitro as well as in vivo cytotoxicity of 2-chlorodeoxyadenosine is described. Thus, 2-chloro-9,1'-beta.-2'-deoxy-2'-fluoro-D-arabinofuranosyl adenine (II) was prepd. starting from 1,3'-di-O-acetyl-5'-O-benzoyl-2'-deoxy-2'-fluoro-.beta.-D-arabinose via 3'-O-acetyl-5'-O-benzoyl-2'-deoxy-2'-fluoro-D-arabinofuranosyl bromide and 2,6'-dichloro-9,1'-(3'-O-acetyl-5'-O-benzoyl-2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-9-purine. Tablets were prepd. contg. II 1, starch 40, modified starch 10, Mg stearate 1-5 mg and CaHPO₄ q.s.

IT 123318-82-1

RL: BIOL (Biological study)

(pharmaceuticals contg., for treating autoimmune and monocyte-mediated diseases)

IT 123318-82-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, for treating autoimmune or monocyte-mediated diseasesmonocyte-mediated disease)

L5 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:595337 HCAPLUS

DOCUMENT NUMBER: 111:195337

TITLE: Preparation of purine derivatives as antivirals and pharmaceutical compositions containing them

INVENTOR(S): Lambert, Robert Wilson; Martin, Joseph Amstrong

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE


APPLICATION NO. DATE

Searched by M. Smith

EP 314011	A2	19890503	EP 1988-117572	19881021
EP 314011	A3	19900411		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8807903	A	19890628	ZA 1988-7903	19881021
AU 8824160	A1	19890504	AU 1988-24160	19881024
CS 270249	B2	19900613	CS 1988-7057	19881025
HU 48270	A2	19890529	HU 1988-5588	19881026
HU 199502	B	19900228		
FI 8804954	A	19890501	FI 1988-4954	19881027
DK 8806037	A	19890501	DK 1988-6037	19881028
NO 8804830	A	19890502	NO 1988-4830	19881028
NO 168037	B	19910930		
NO 168037	C	19920108		
JP 01149797	A2	19890612	JP 1988-271119	19881028
CN 1038102	A	19891220	CN 1988-107516	19881028

PRIORITY APPLN. INFO.: GB 1987-25466 19871030
GB 1988-16612 19880713

OTHER SOURCE(S): MARPAT 111:195337
GI



- AB The title compds. [I; R1 = Cl, N3, NH2; R2 = H, (substituted) trityl; R3 = H, OH, PhOC(S)O] and the amido derivs. and Schiff bases of I [R1 = Cl, N3, NH2; R2 = R3 = H], useful as antiviral agents for humans and animals, esp. useful for the prevention and treatment of infections caused by HIV (no data), are prepd. I [R1 = Cl, R2 = trityl, R3 = H] in CHCl3 was treated with HCl to give I [R1 = Cl, R2 = R3 = H].
- IT 123318-82-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antiviral agent)

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:10:17 ON 25 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

Searched by M. Smith

provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1
DICTIONARY FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can l4

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> fil hcaplu

FILE 'HCAPLUS' ENTERED AT 15:26:06 ON 25 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Apr 2003 VOL 138 ISS 18


FILE LAST UPDATED: 24 Apr 2003 (20030424/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d stat que

```
L2      1 SEA FILE=REGISTRY "9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUO
        RO-.BETA.-D-ARABINOFURANOSYL)-"/CN
L3      SEL L2 1- CHEM :          3 TERMS
L4      43 SEA FILE=HCAPLUS L3
L5      19 SEA FILE=HCAPLUS L4 AND (SYNTHES? OR PREP? OR MANUF?)
L9      STR
```

Searched by M. Smith



VAR G1=21/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

L11 22 SEA FILE=REGISTRY SSS FUL L9

L12 20 SEA FILE=HCAPLUS L11/P

L13 7 SEA FILE=HCAPLUS L12 NOT L5

=> d ibib abs hitrn l13 1-7

L13 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:674994 HCAPLUS

DOCUMENT NUMBER: 136:20198

TITLE: Synthesis and biological activity of
4'-C-hydroxymethyl-2'-fluoro-D-arabinofuranosylpurine
nucleosides

AUTHOR(S): Shortnacy-Fowler, A. T.; Tiwari, K. N.; Montgomery, J.
A.; Secrist, J. A., III

CORPORATE SOURCE: Southern Research Institute, Birmingham, AL,
35255-5305, USA

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2001),
20(4-7), 747-750

CODEN: NNNAFY; ISSN: 1525-7770

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 4'-C-hydroxymethyl-2'-fluoro-D-arabinofuranosylpurine
nucleosides was prepd. and evaluated for cytotoxicity in human tumor cell
lines. A convenient synthesis of the carbohydrate precursor
4-C-hydroxymethyl-3,5-di-O-benzoyl-2-fluoro-.alpha.-D-arabinofuranosyl
bromide (13) was developed. Coupling of 13 with the sodium salt of
2,6-dichloropurine led to five target purine nucleosides.

IT 374782-67-9P 374782-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)


(prepn., antitumor activity, and cytotoxicity of 4'-C-hydroxymethyl-2'-
fluoro-D-arabinofuranosylpurine nucleosides)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

Searched by M. Smith

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:10640 HCAPLUS
 DOCUMENT NUMBER: 124:202895
 TITLE: Convergent synthesis and cytostatic properties of
 2-chloro-2'-deoxy-2'-fluoroadenosine and its N7-isomer
 AUTHOR(S): Zaitseva, Galina V.; Sivets, Grigorii G.;
 Kazimierczuk, Zygmunt; Vilpo, Juhani A.; Mikhailopulo,
 Igor A.
 CORPORATE SOURCE: Inst. Bioorg. Chem., Byelorussian Acad. Sci., Minsk,
 220141, Belarus
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995),
 5(24), 2999-3002
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:202895
 GI



- AB Glycosylation of trimethylsilylated 2,6-dichloropurine with acetate I in anhyd. MeCN was investigated. In the presence of SnCl₄, the reaction was regio- and stereoselective affording N7-.beta.-glycoside II (86%). The use of TMS-TfI instead of SnCl₄ afforded a .apprxeq.9:1 mixt. of the N9-.beta.- and -.alpha.-glycosides III (90%, combined). The title nucleosides were tested for their cytotoxicity.
- IT 156357-18-5P, 2-Chloro-2'-deoxy-2'-fluoroadenosine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (convergent synthesis and cytostatic properties of chlorodeoxyfluoroadenosines)
- IT 174462-89-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (convergent synthesis and cytostatic properties of chlorodeoxyfluoroadenosines)

L13 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:448387 HCAPLUS

Searched by M. Smith

DOCUMENT NUMBER: 122:255520
TITLE: Search for New Purine- and Ribose-Modified Adenosine Analogs as Selective Agonists and Antagonists at Adenosine Receptors
AUTHOR(S): Siddiqi, Suhaib M.; Jacobson, Kenneth A.; Esker, John L.; Olah, Mark E.; Ji, Xiao-duo; Melman, Neli; Tiwari, Kamal N.; Secrist, John A., III; Schneller, Stewart W.; et al.
CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892-0810, USA
SOURCE: Journal of Medicinal Chemistry (1995), 38(7), 1174-88. CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The binding affinities at rat A1, A2a, and A3 adenosine receptors of a wide range of derivs. of adenosine have been detd. Sites of modification include the purine moiety (1-, 3-, and 7-deaza; halo, alkyne, and amino substitutions at the 2- and 8-positions; and N6-CH2-ring, -hydrazino, and -hydroxylamino) and the ribose moiety (2'-, 3'-, and 5'-deoxy; 2'- and 3'-O-methyl; 2'-deoxy 2'-fluoro; 6'-thio; 5'-uronamide; carbocyclic; 4'- and 3'-methyl; and inversion of configuration). (-)- And (+)-5'-noraristeromycin were 48- and 21-fold selective, resp., for A2a vs A1 receptors. 2-Chloro-6'-thioadenosine displayed a Ki value of 20 nM at A2a receptors (15-fold selective vs A1). 2-Chloroadenine-9-(.beta.-L-2'-deoxy-6'-lyxofuranoside) displayed a Ki value of 8 .mu.M at A1 receptors and appeared to be an antagonist, on the basis of the absence of a GTP-induced shift in binding vs a radiolabeled antagonist (8-cyclopentyl-1,3-dipropylxanthine). 2-Chloro-2'-deoxyadenosine and 2-chloroadenine-9-(.beta.-D-6'-thioarabinoside) were putative partial agonists at A1 receptors, with Ki values of 7.4 and 5.4 .mu.M, resp. The A2a selective agonist 2-(1-hexynyl)-5'-(N-ethylcarbamoyl)adenosine displayed a Ki value of 26 nM at A3 receptors. The 4'-Me substitution was poorly tolerated, yet when combined with other favorable modifications, potency was restored. Thus, N6-benzyl-4'-methyladenosine-5'-(N-methyluronamide) displayed a Ki value of 604 nM at A3 receptors and was 103- and 88-fold selective vs A1 and A2a receptors, resp. This compd. was a full agonist in the A3-mediated inhibition of adenylate cyclase in transfected CHO cells. The carbocyclic analog of N6-(3-iodobenzyl)adenosine-5'-(N-methyluronamide) was 2-fold selective for A3 vs A1 receptors and was nearly inactive at A2a receptors.

IT 156357-18-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(purine- and ribose-modified adenosine analogs as selective agonists and antagonists at adenosine receptors)

L13 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:483851 HCAPLUS
DOCUMENT NUMBER: 121:83851
TITLE: Synthesis and biologic activity of purine 2'-deoxy-2'-fluoro-ribonucleosides
AUTHOR(S): Thomas, H. Jeanette; Tiwari, Kamal N.; Clayton, Sarah Jo; Secrist, John A., III; Montgomery, John A.
CORPORATE SOURCE: South. Res. Inst., Birmingham, AL, 35255-5305, USA
SOURCE: Nucleosides & Nucleotides (1994), 13(1-3), 309-23

DOCUMENT TYPE:
LANGUAGE:
GI

CODEN: NUNU05; ISSN: 0732-8311
Journal
English



AB The synthesis of 3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-ribofuranosyl bromide and its reaction with 2,6-dichloropurine by fusion and with mercuric cyanide catalysis is described. The resulting 2,6-dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-.beta.-D-ribofuranosyl)purine was converted to 2'-deoxy-2'-fluoro-ribonucleosides, e.g. I (R = H, Cl, F). These nucleosides were cytotoxic to a no. of cell lines in culture. I (R = Cl, F) gave modest increases in lifespan when tested against the P388 leukemia in mice.

IT 156357-18-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antitumor activity of)

L13 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:459409 HCAPLUS

DOCUMENT NUMBER: 107:59409

TITLE: 2-Fluoro-arabinofuranosyl purine nucleosides as neoplasm inhibitors and parasiticides

INVENTOR(S): Watanabe, Kyoichi A.; Chu, Chung K.; Fox, Jack J.

PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 219829	A2	19870429	EP 1986-114412	19861017
EP 219829	A3	19880504		
EP 219829	B1	19921230		
R: DE, ES, FR, GB				
US 4751221	A	19880614	US 1985-789072	19851018
CA 1271192	A1	19900703	CA 1986-520646	19861016

Searched by M. Smith

JP 62161797 A2 19870717 JP 1986-245654 19861017
 JP 07023395 B4 19950315
 US 4918179 A 19900417 US 1988-189148 19880502
 PRIORITY APPLN. INFO.: US 1985-789072 19851018
 GI



AB The title compds. (I; R1, R2 = H, acyl, aroyl; R3, R4 = H, halo, OR5, SR5, NR5R6, decylimino; R5, R6 = H, alkyl, aralkyl, acyl) were prepd. as neoplasm inhibitors and parasiticides. I (R1 = R2 = H, R3 = SH, R4 = NH2) was refluxed in H2O with Raney Ni to give I (R1 = R2 = R3 = H, R4 = NH2) (II). II had an ID50 of 2.0 .mu.M against mouse L 1210 leukemia cells.

IT 109303-89-1P 109303-90-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as parasiticide and neoplasm inhibitor)

L13 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1986:491327 HCAPLUS
 DOCUMENT NUMBER: 105:91327
 TITLE: Treatment of tumors in mammals
 INVENTOR(S): Grindey, Gerald Burr; Hertel, Larry Wayne
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
 SOURCE: Eur. Pat. Appl., 60 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 184365	A2	19860611	EP 1985-308547	19851125
EP 184365	A3	19880127		
EP 184365	B1	19930804		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8509008	A	19870729	ZA 1985-9008	19851125
CA 1264738	A1	19900123	CA 1985-496077	19851125
IL 77133	A1	19910131	IL 1985-77133	19851125
AT 92499	E	19930815	AT 1985-308547	19851125
DK 162965	B	19920106	DK 1985-5496	19851128
DK 162965	C	19920601		
AU 8550555	A1	19860612	AU 1985-50555	19851202

Searched by M. Smith

AU 581269	B2	19890216		
JP 61148193	A2	19860705	JP 1985-273161	19851203
JP 06037394	B4	19940518		
CN 85109409	A	19860827	CN 1985-109409	19851203
CN 1020194	B	19930331		
HU 39188	A2	19860828	HU 1985-4620	19851203
HU 194273	B	19880128		
ES 549547	A1	19870801	ES 1985-549547	19851203
US 5061793	A	19911029	US 1988-163571	19880303
US 5464826	A	19951107	US 1994-280687	19940726

PRIORITY APPLN. INFO.:

	US 1984-677783	19841204
	US 1985-786419	19851010
	EP 1985-308547	19851125
	US 1988-163571	19880303
	US 1991-746441	19910816
	US 1993-99268	19930729

AB 2'-Deoxy-2',2'-difluoronucleosides are prepd. as cytostatic agents for neoplasm treatment. For example, 1-(4-amino-2-oxo-1H-pyrimidin-1-yl)-2-deoxy-2,2-difluororibose (I) (20.0 mg/kg i.p. on days 1, 5, and 9 after tumor implantation) gave 92-100% inhibition of 6C3HED lymphosarcoma, CA755 adenocarcinoma, P1534J lymphocytic leukemia, and X5563 myeloma in mice. I was prepd. by reaction of 3,5-bis(tert-butyldimethylsiloxy)-1-methanesulfonyloxy-2-deoxy-2,2-difluororibose with bis(trimethylsilyl)-N-acetylcytosine and deprotection. Tablets were prepd. contg. I 250, microcryst. cellulose 400, SiO₂ 10, and stearic acid 5 mg.

IT 103828-79-1P 103828-80-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as neoplasm inhibitor)

L13 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1970:44060 HCAPLUS

DOCUMENT NUMBER: 72:44060

TITLE: Nucleosides. LX. Fluorocarbohydrates. 22.
 Synthesis of 2-deoxy-2-fluoro-D-arabinose and
 9-(2-deoxy-2-fluoro-.alpha. and .beta.-D-arabinofuranosyl)adenines

AUTHOR(S): Wright, John Arthur; Taylor, Norman F.; Fox, Jack J.

CORPORATE SOURCE: Sloan-Kettering Inst. for Cancer Res., New York, NY, USA

SOURCE: Journal of Organic Chemistry (1969), 34(9), 2632-35
 CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nucleophilic attack of KHF₂ on Me 2,3-anhydro-5-O-benzyl-.alpha.-D-ribose occurred largely at the 2 position (in contrast to the .beta.-D anomer) and leads to Me 5-O-benzyl-2-deoxy-2-fluoro-.alpha.-D-arabinoside (I), thus achieving the first direct synthesis of a 2-fluoropentose derivative. From I, 2-deoxy-2-fluoro-D-arabinose is obtained. Fusion of 1,3-di-O-acetyl-5-O-benzyl-2-deoxy-2-fluoro-D-arabinose with 2,6-dichloropurine affords a readily resolved .alpha.-.beta. mixt. of 9-glycosyl-purine nucleosides, which are converted into 9-(2-deoxy-2-fluoro-.alpha.-and .beta.-D-arabinofuranosyl)adenines. Confirmation of the anomeric configuration of these nucleosides is obtained by conversion into their 5'-toluenesulfonates and by cyclization of the .beta. anomer to its 3,5'-cyclonucleoside.

IT 20187-81-9P 20227-40-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

=> select hit rn 113 1-7
E1 THROUGH E10 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:30:22 ON 25 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1
DICTIONARY FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s el-el0

1 156357-18-5/BI
(156357-18-5/RN)
1 103828-79-1/BI
(103828-79-1/RN)
1 103828-80-4/BI
(103828-80-4/RN)
1 109303-89-1/BI
(109303-89-1/RN)
1 109303-90-4/BI
(109303-90-4/RN)
1 174462-89-6/BI
(174462-89-6/RN)
1 20187-81-9/BI
(20187-81-9/RN)
1 20227-40-1/BI
(20227-40-1/RN)
1 374782-67-9/BI
(374782-67-9/RN)
1 374782-68-0/BI
(374782-68-0/RN)

L14 10 (156357-18-5/BI OR 103828-79-1/BI OR 103828-80-4/BI OR 109303-89-1/BI OR 109303-90-4/BI OR 174462-89-6/BI OR 20187-81-9/BI OR 20227-40-1/BI OR 374782-67-9/BI OR 374782-68-0/BI)


=> d ide can 114 1-10

L14 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 374782-68-0 REGISTRY

Searched by M. Smith

CN 9H-Purin-6-amine, 2-chloro-9-[2-deoxy-2-fluoro-4-C-(hydroxymethyl)-.beta.-
D-threo-pentofuranosyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H13 Cl F N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:20198

REFERENCE 2: 136:6249

L14 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 374782-67-9 REGISTRY
CN 9H-Purin-6-amine, 2-chloro-9-[2-deoxy-2-fluoro-4-C-(hydroxymethyl)-.alpha.-
D-threo-pentofuranosyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H13 Cl F N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Searched by M. Smith


2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:20198

REFERENCE 2: 136:6249

L14 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 174462-89-6 REGISTRY
CN 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-.alpha.-D-ribofuranosyl)-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H11 Cl F N5 O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:202895

L14 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 156357-18-5 REGISTRY
CN Adenosine, 2-chloro-2'-deoxy-2'-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Chloro-2'-deoxy-2'-fluoroadenosine
FS STEREOSEARCH
MF C10 H11 Cl F N5 O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.

Searched by M. Smith



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:346991

REFERENCE 2: 124:202895

REFERENCE 3: 122:255520

REFERENCE 4: 121:83851

L14 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2003 ACS

RN 109303-90-4 REGISTRY

CN Benzamide, N-[9-(3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-2-chloro-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C26 H21 Cl F N5 O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

Searched by M. Smith

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 107:59409

L14 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2003 ACS

RN 109303-89-1 REGISTRY

CN Acetamide, N-[9-(3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-2-chloro-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C21 H19 Cl F N5 O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 107:59409

L14 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2003 ACS

RN 103828-80-4 REGISTRY

CN Adenosine, 2-chloro-2'-deoxy-2',2'-difluoro- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C10 H10 Cl F2 N5 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



Searched by M. Smith

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 131:223117

REFERENCE 2: 130:346991

REFERENCE 3: 105:91327

L14 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 103828-79-1 REGISTRY
CN 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2,2-difluoro-.alpha.-D-erythro-
pentofuranosyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H10 Cl F2 N5 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 105:91327

L14 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 20227-40-1 REGISTRY
CN Adenine, 9-(5-O-benzyl-2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-2-
chloro- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H17 Cl F N5 O3
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 72:44060

L14 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2003 ACS
RN 20187-81-9 REGISTRY
CN Adenine, 9-(5-O-benzyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-2-chloro- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H17 Cl F N5 O3
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 72:44060

=> d stat que 126 nos

L2 1 SEA FILE=REGISTRY "9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)-"/CN
L3 SEL L2 1- CHEM : 3 TERMS
L4 43 SEA FILE=HCAPLUS L3

Searched by M. Smith

L5 19 SEA FILE=HCAPLUS L4 AND (SYNTHES? OR PREP? OR MANUF?)
L9 STR
L11 22 SEA FILE=REGISTRY SSS FUL L9
L12 20 SEA FILE=HCAPLUS L11/P
L13 7 SEA FILE=HCAPLUS L12 NOT L5
L16 1804 SEA FILE=REGISTRY 2(W)CHLORO?(W)6(W) (ALKOXY? OR METHOXY? OR
ETHOXY?)
L17 9543 SEA FILE=REGISTRY ARABINOFURANOSYL?
L18 113365 SEA FILE=REGISTRY PURIN?
L19 13471 SEA FILE=REGISTRY ADENINE?
L21 1420 SEA FILE=HCAPLUS 2(W)CHLORO?(W)6(W) (ALKOXY? OR METHOXY? OR
ETHOXY?) OR L16
L22 13889 SEA FILE=HCAPLUS L17 OR ARABINOFURANOSYL?
L23 301642 SEA FILE=HCAPLUS L18 OR L19 OR PURIN? OR ADENIN?
L24 3316 SEA FILE=HCAPLUS L22(L)L23
L25 1 SEA FILE=HCAPLUS L24 AND L21
L26 1 SEA FILE=HCAPLUS L25 NOT (L5 OR L13)

=> d ibib abs hitstr

L26 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:445941 HCAPLUS
DOCUMENT NUMBER: 115:45941
TITLE: 6-Methoxypurine arabinoside as a selective and potent
inhibitor of varicella-zoster virus
AUTHOR(S): Averett, Devron R.; Koszalka, George W.; Fyfe, James
A.; Roberts, Grace B.; Purifoy, Dorothy J. M.;
Krenitsky, Thomas A.
CORPORATE SOURCE: Wellcome Res. Lab., Research Triangle Park, NC, 27709,
USA
SOURCE: Antimicrobial Agents and Chemotherapy (1991), 35(5),
851-7
CODEN: AMACQ; ISSN: 0066-4804
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Seven 6-alkoxypurine arabinosides were synthesized and evaluated for in vitro activity against varicella-zoster virus (VZV). The simplest of the series, 6-methoxypurine arabinoside (ara-M), was the most potent, with 50% inhibitory concns. ranging from 0.5 to 3 .mu.M against eight strains of VZV. This activity was selective. The ability of ara-M to inhibit the growth of a variety of human cell lines was at least 30-fold less (50% effective concn., >100 .mu.M) than its ability to inhibit the virus. Enzyme studies suggested the mol. basis for these results. Of the seven 6-alkoxypurine arabinosides, ara-M was the most efficient substrate for VZV-encoded thymidine kinase as well as the most potent antiviral agent. In contrast, it was not detectably phosphorylated by any of the 3 major mammalian nucleoside kinases. Upon direct comparison, ara-M was appreciably more potent against VZV than either acyclovir or adenine arabinoside (ara-A). However, in the presence of an adenosine deaminase inhibitor, the arabinosides of adenine and 6-methoxypurine were equipotent but not equally selective; the adenine congener had a much less favorable in vitro chemotherapeutic index. Again, this result correlated with data from enzyme studies in that ara-A, unlike ara-M, was a substrate for 2 mammalian nucleoside kinases. Unlike acyclovir and ara-A, ara-M had no appreciable activity against other viruses of the herpes group. The potency and selectivity of ara-M as an anti-VZV agent in vitro justify its further study.

IT 91969-06-1P 121032-23-3P 121032-29-9P

Searched by M. Smith

121032-30-2P 134978-72-6P 134978-73-7P
134978-74-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and antiviral activity of, structure in relation to)

RN 91969-06-1 HCAPLUS

CN 9H-Purine, 9-.beta.-D-arabinofuranosyl-6-methoxy- (7CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121032-23-3 HCAPLUS

CN 9H-Purine, 9-.beta.-D-arabinofuranosyl-6-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121032-29-9 HCAPLUS

CN 9H-Purin-2-amine, 9-.beta.-D-arabinofuranosyl-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121032-30-2 HCAPLUS

CN 9H-Purine, 9-.beta.-D-arabinofuranosyl-6-propoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 134978-72-6 HCAPLUS

CN 9H-Purine, 9-.beta.-D-arabinofuranosyl-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 134978-73-7 HCAPLUS

CN 9H-Purine, 9-.beta.-D-arabinofuranosyl-2-chloro-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 134978-74-8 HCAPLUS

CN 9H-Purin-2-amine, 9-.beta.-D-arabinofuranosyl-6-ethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by M. Smith